Editas And Intellia: Strategic Shifts And Long-Term Investment Potential
A look at Intellia Therapeutics, Inc. and Editas Medicine, Inc., including their restructuring and pipeline prioritization.
Hennion & Walsh Asset Management Inc. Has $1.41 Million Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)
Hennion & Walsh Asset Management Inc. lifted its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 125.2 ...
Intellia Loses 21.6% in a Week: How Should You Play the Stock?
NTLA stock falls more than 21% in a week after the company announced strategic priorities and key anticipated milestones for 2025. We advise prospective investors to stay on the sidelines for now.
Intellia Therapeutics: Buying The Path To Commercialization
Financial writer recommends buying Intellia Therapeutics, Inc. stock as it restructures, focusing on late-stage programs for ...
GlobalData on MSN6d
Intellia slashes workforce by 27% to focus on late stage CRISPR candidates
Intellia expects to incur charges of $8m associated with the reorganisation, which will likely be incurred in Q1 2025.
The Zacks Analyst Blog Moderna, Regeneron, Intellia Sage and GSK
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the ...
bovnews1d
What’s Fueling Intellia Therapeutics Inc (NTLA) Stock’s -53.57% Loss Below Its 200-Day SMA?
Intellia Therapeutics Inc (NTLA) stock saw a decline, ending the day at $9.42 which represents a decrease of $-0.29 or -2.99% from the prior close of $9.71. The stock opened at $9.76 and touched a low ...
AdvisorNet Financial Inc Buys 4,950 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)
AdvisorNet Financial Inc grew its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 96.4% during the 4th quarter, HoldingsChannel reports. The fund owned 10,085 shares of the company ...
Bronstein, Gewirtz & Grossman, LLC Is Investigating Intellia Therapeutics, Inc. (NTLA) And Encourages Stockholders to Connect
NEW YORK CITY, NY / ACCESSWIRE / January 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...
Intellia ATTR, HAE studies progressing as planned, says JPMorgan
After having hosted Intellia Therapeutics ’ CEO John Leonard at the firm’s healthcare conference, JPMorgan said management “shed light” on the thinking behind the strategi ...
JD Supra2d
The Not-So-Safe Harbor for Research Tools: Lessons From the District of Delaware
In BlueAllele Corp. v. Intellia Therapeutics, Inc., 2024 U.S. Dist. Lexis 222094 (D. Del. Dec. 9, 2024)1, the District of ...
Nasdaq5d
13 Analysts Have This To Say About Intellia Therapeutics
Providing a diverse range of perspectives from bullish to bearish, 13 analysts have published ratings on Intellia Therapeutics (NASDAQ:NTLA) in the last three months. The table below offers a ...